Foundations  Blogs   Videos   Basic Reading   Medical Reading   Approvals   

Support Groups   Programs in NET cancer   Resource page


Targeted alpha therapy receives award in US

Outlines use of Alpha Radiation in treatment of NETs. The trial is ongoing.

NETs of Prostate inhibited by PHA-739358

This short piece outlines a particularly nasty NET and a promising possible treatment.

Poster #1 outlining results of Phase 2 Trial of telotristat etiprate

Poster #2 outlining results of Phase 2 Trial of telotristat etiprate

Presentation Slides from telotristat etiprate presentation at NANETS

Phase 2 study results for telotristat etiprate in patients with CS to be presented at NANETS

The four items above give a fairly clear overview of the success of the Phase 2 Trial of telotristat etiprate as presented at the October 20-22 NANETS conference in Minneapolis. The results merit further study, according to the presenters. Lead author on the study was Matthew Kulke from DFCI.

These are the results of a Phase I  trial of an entirely new anti-tumor drug. The substance is called NKP-1339. The trial was conducted in Phoenix, Arizona. It had a significant effect on a non-pancreatic NET. It created regression in that patient”s tumor. A Phase I trial does not mean much–and FDA approval is still clearly years away even if everything goes well from here. But the study is promising.

This is a link to the announcement of a trial for a new radiation treatment for neuroendocrine tumors. The trial is taking place in Houston, Texas. This treatment has been available in Europe previously. It uses LU-177 Octreotate.

(If you learn of or know of trials of new drugs or treatments for NECs or CS, please e-mail me at and I will post them here. Walking with Jane also receives mail at P.O. Box 9721, Fall River, MA 02720.)

 Foundations  Blogs   Videos   Basic Reading   Medical Reading  Approvals   

Support Groups  Resource page